Bronchogenic Carcinoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

CCND1
CCND1 Amplification

Overview

NCI Definition: A lung carcinoma arising from the bronchial epithelium. [1]

Clinical Trials

View Clinical Trials for Bronchogenic Carcinoma

There is 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains bronchogenic carcinoma as an inclusion criterion, 1 is phase 2 (1 open).

CCND1 is the most frequent gene inclusion criterion for bronchogenic carcinoma clinical trials [3].

Trials Investigating Bronchogenic Carcinoma by Gene and Recruiting Status

Palbociclib is the most common intervention in bronchogenic carcinoma clinical trials.

Drugs Being Investigated in Bronchogenic Carcinoma Trials by Recruiting Status

Significant Genes in Bronchogenic Carcinoma

AKT1 +

AKT1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK +

ALK is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM +

ATM is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR +

ATR is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 +

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 +

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 +

CCND1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 +

CDK12 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 +

CDK4 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 +

CDK6 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A +

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 +

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CSF1R +

CSF1R is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPCAM +

EPCAM is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB3 +

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EXO1 +

EXO1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA +

FANCA is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET +

MET is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 +

MLH1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 +

MLH3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A +

MRE11A is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 +

MSH2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 +

MSH3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 +

MSH6 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MST1R +

MST1R is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR +

MTOR is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN +

NBN is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRG1 +

NRG1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 +

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 +

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 +

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 +

PALB2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PCNA +

PCNA is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA +

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 +

PMS1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 +

PMS2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLD1 +

POLD1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE +

POLE is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C +

RAD51C is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC1 +

RFC1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 +

RFC2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 +

RFC3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 +

RFC4 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 +

RFC5 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 +

ROS1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 +

RPA1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 +

RPA2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 +

RPA3 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 +

RPA4 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SSBP1 +

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 +

TSC1 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 +

TSC2 is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL +

VHL is an inclusion eligibility criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Bronchogenic Lung Carcinoma, Bronchial Carcinoma, Bronchiogenic Carcinoma, CARCINOMA, BRONCHIAL, MALIGNANT

Parent(s)

Lung Carcinoma

Children

Superior Sulcus Lung Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.